Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...

First, let's back up a bit and take a look at the Moderna story, from the glory days of a few years ago to its troubles today ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.